Paper
0
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Authors
Frédéric Pouliot,Fred Saad
Étienne Rousseau,Patrick Richard,Atefeh Zamanian,Stephan Probst,Éric Lévesque,Vincent Castonguay,Nicolas Marcoux,Michele Lodde,Daniel Juneau,Zineb Hamilou,Jean‐Baptiste Lattouf,François-Alexandre Buteau,Michel Pavic,Jean‐François Castilloux,Bertrand Neveu,Guillaume Bouvet,Catherine Allard,Amélie Têtu,Brigitte Guérin
+19 authors
,Jean‐Mathieu BeauregardJournal
Published
Sep 26, 2024
Show more
Save
Tip0
TipSave
Abstract
Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.